Findings
========

Background and aim
------------------

In the past ten years an increasing number of dendritic cell (DC)-based therapeutic vaccination trials against HIV-1 has been developed augmenting the general interest in dendritic cell biology and in the interaction between this innate immune cell and HIV-1 \[[@B1]\].

There are at least two major subtypes of DC: myeloid and plasmacytoid DC. Myeloid DC (mDC) are professional antigen presenting cell capable to initiate cellular immune response. On the other hand plasmacytoid DC (pDC) exhibit an exuberant anti-viral response through the production of high levels of IFN-alpha \[[@B2]\].

In HIV infection it has been demonstrated a reduction in absolute number of mDC and pDC, especially in patients with active HIV-1 replication \[[@B3]\], suggesting a key role of DC in controlling viral load. Moreover the preserved functionality of pDC isolated from "elite controllers" may be one of the mechanisms involved in the control of HIV-1 viremia in these subjects \[[@B4]\].

Myeloid DC obtained culturing peripheral blood monocytes with IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (IL4-DC) have been implied in immunotherapy of cancer and, most recently, of HIV infection \[[@B5]\].

Alternative protocols for maturation of DC included the use of interferon (IFN)-α instead of IL-4 (IFN-DC). Type I interferons markedly promotes the differentiation of peripheral blood monocytes into DC. IFN-DC are able to induce a strong cytotoxic response and cross priming of CD8+ T cells against viral or tumoral antigens both *in vitro* and *in vivo*\[[@B6],[@B7]\]. IFN-DC exhibit a combined phenotype of mDC and pDC associated with characteristics of natural killer (NK) cells \[[@B8],[@B9]\].

In the context of therapeutic vaccine against HIV-1, the possibility of using IFN-DC would provide several advantages, including augmented antigen presentation, cytotoxic function and type I IFN production.

Considering the key role of NLRP3-inflammasome during maturation and activation of DC in mice \[[@B10]\], our group has recently started working on inflammasome activation in DC obtained *in vitro* from peripheral blood monocytes. DC response to HIV-1 through NLRP3-inflammasome could be important in HIV vaccine development especially in DC-based immune treatment.

We demonstrated that human monocyte-derived IL4-DC presented an inducible activation of NLRP3-inflammasome by lipopolysaccharide/LPS as well as by HIV-1 \[[@B10]\]. It is interesting to note that the same differentiation protocol used in monocytes isolated from HIV + individuals (HIV-DC) showed a different response. NLRP3-inflammasome was not induced by LPS or HIV in HIV-DC, however its basal activation resulted higher in these cells compared with DC from healthy subjects (HC-DC), letting us hypothesize an "unresponsive" condition of HIV-DC that may affect vaccine preparation \[[@B10]\].

In this study we investigate the rate of inflammasome expression and activation in monocyte-derived IFN-DC obtained from healthy individuals and HIV + patients. Our findings could be of interest considering the on-going research about DC manipulation and therapeutic strategies for AIDS involving DC-based immune-vaccines.

Individuals and methods
-----------------------

15 healthy subjects (HC, 7 males, 8 females; mean age 30 ± 5 standard deviation/SD) and 10 HIV-1-positive volunteers (HIV+, 8 males, 2 females; mean age 28 ± 2 SD) were recruited from "Hospital das Clinicas" (University of São Paulo, Brazil). HIV + patients had a CD4+ lymphocytes count \> 500 cells/μl and were "naïve" for treatment. All the patients have been infected for more than 5 years and they do not presented specific clinical symptoms at the moment of recruitment. Written informed consent was obtained according to the protocol of "Hospital das Clinicas" Ethical Committee (CAPPesq) (São Paulo, Brazil).

Monocytes were isolated by adherence from peripheral blood monocytes obtained by centrifugation over Ficoll-Paque gradient and cultured at 1.5-2 × 10^6^/ml in AIM-V medium (*Gibco*) containing 50 ng/ml GM-CSF (*Peprotech*) and 50 ng/ml IL-4 (*Peprotech*) or IFN-α (Schering-Plough) (IL4-DC and IFN-DC, respectively). On day 5, DC were pulsed with 0.5 × 10^9^ particles of alditrithiol-2 inactivated HIV (as reported in \[[@B10]\]) for 4 hours. Supernatants were harvested and used for IL-1β secretion dosage; cells were lysed for mRNA isolation and gene expression analysis.

Total RNA was isolated using the RNAqueous micro kit (*Ambion, Life Technologies*) and retro-transcribed with the SuperScritp-II kit (*Invitrogen*). *NLRP1, NLRP3, NLRC4, AIM2, CASP1, IL1B* genes were amplified with specific TaqMan® Gene Expression Assays (*Applied Biosystems*) using the ABI 7300 platform (*Applied Biosystems*). *ACTB* was the housekeeping gene used for normalization. Fold-change (FC) genes expression was calculated comparing stimulated (+HIV) and untreated/resting cells as 2^-∆∆Ct^ following the indications of Livak et al. \[[@B11]\].

The secreted IL-1β was evaluated with ELISA (*BD Biosciences Pharmigen)*. Results were expressed as pg/ml.

One-way Anova analysis was used to compare different groups and a significance level of 0.05 was applied. Prism 5.01 software (GraphPad Software, Inc) was used for done graphs and statistical analysis.

Results and discussion
======================

We evaluated the expression of *NLRP1*, *NLRP3, NLRC4, AIM2, CASP1, IL1B* genes in DC from 15 healthy subjects obtained through IL-4 or IFN-α differentiation protocol and pulsed with chemically inactivated HIV-1. IL-1β secretion was also evaluated as marker of inflammasome activation.

Cells differentiation state was checked by flow cytometry looking at granulosity and common DC markers (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). No significant differences were observed in differentiation markers between IL4-DC and IFN-DC.

When genes expression was evaluated the following criteria were applied: only samples with Ct \< 35 and with a positivity of at least 80% of the samples were included in the analysis; normalized data (∆Ct) must be homogenous for all the genes in each group (t test p-value \> 0.05); FC \> 1.5 or \<0.5 were taken in account as up-regulation or down-regulation.

HIV induced increased expression (FC \> 1.5) of *NLRP1, NLRP3, AIM2, CASP1* and *IL1B* in IL4-DC, and of *NLRC4, AIM2, CASP1* and *IL1B* in IFN-DC (Figure [1](#F1){ref-type="fig"}A). However the rate of induction appeared to be significantly reduced in IFN-DC compared to IL-4 DC (p \< 0.003).

![**Inflammasome genes expression in IL4-DC and IFN-DC from healthy subjects pulsed with HIV-1.***mRNA* expression 4 hours after stimulation of IL4-DC and IFN-DC with chemically inactivated HIV-1 was reported for *NLRP1, NLRP3, NLRC4, AIM2, CASP1* and *IL1B* genes **(1A)***.* Fold-change (FC) in mRNA expression of each gene was calculated with respect to the untreated condition as 2^-∆∆Ct^ where ∆∆Ct = ∆Ct HIV- ∆Ct Untreated. Results are expressed as average (AVG) of 2^-∆∆Ct^ ± standard error, n = 20. All the Ct values were normalized against *ACTB* Ct (∆Ct). Stacked lines showed FC threshold (0.5-1.5). 1-way Anova analysis was used to compare genes expression in IFN-DC and IL4-DC. \* = p \< 0.05. **(1B)** Supernatants of IFN-DC and IL4-DC stimulated or not with HIV-1 were analysed for the presence of secreted IL-1β. Results are expressed as the average concentration (pg/ml) ± standard error. 1-way Anova analysis was used to compare IFN-DC and IL4-DC. \* = p \< 0.05.](1742-6405-10-35-1){#F1}

Of note HIV-1 was able to increase *NLRP3* expression in IL4-DC (FC = 22.47), but it was not able to do the same in IFN-DC (FC = 1.24) (p \< 0.003) (Figure [1](#F1){ref-type="fig"}A).

These differences in inflammasome genes expression between IL4-DC and IFN-DC were emphasized by the results obtained from IL-1β secretion analysis in DC supernatants. HIV induced a significant increase of the pro-inflammatory cytokine in IL4-DC (+HIV = 186.5 pg/ml versus Untreated = 74.87 pg/ml; p = 0.026) but not in IFN-DC (+HIV = 21,88 pg/ml versus Untreated = 8,65 pg/ml; p = 0.301) (Figure [1](#F1){ref-type="fig"}B). Basal secretion of IL4-DC appeared augmented compared to IFN-DC however not in a statistically significant way.

These findings suggested that chemically inactivated HIV-1 is able to induce NLRP3-inflammasome activation in IL4-DC but not in IFN-DC.

As we previously hypothesized \[[@B10]\] NLRP3-inflammasome could play a role in response against HIV and could participate to full dendritic cell activation and to increased proliferation of specific HIV-induced T cells. However our new findings point out that the protocol implied to differentiate monocytes to DC could affect inflammasome biology. Our results agreed with previously reported data by Guarda et al. \[[@B12]\] about the ability of type I IFNs to suppress pro-IL-1 levels and decrease the activity of NLRP1 and NLRP3-inflammasomes in mice. Moreover it is well known that the activation of NLRP3-inflammasome in DC is related with the ability to induce a Th17 polarization in naïve T cells \[[@B13]\], while IFN-DC are able to induce Th1 but fail to polarize naïve T cells into Th17 \[[@B14]\], letting us hypothesize that in IFN-DC the inflammasomes are not induced.

When DC derived from HIV + individuals were analysed, we observed that HIV was not able to significantly induce any of the inflammasome genes in IL4-DC as well as in IFN-DC (1.5 \< FC \< 0.5) (Figure [2](#F2){ref-type="fig"}A). According to our previous published data \[[@B10]\], in untreated cells IL1-β secretion was higher in HIV-DC compared to HC-DC whatever protocol was used (Figure [1](#F1){ref-type="fig"}B and [2](#F2){ref-type="fig"}B; p = 0.02). Moreover HIV was not able to induce augmented amount of cytokine in IFN-DC or in IL4-DC (Figure [2](#F2){ref-type="fig"}B). We have previously hypothesized that IL4-DC from HIV + individuals presented an increased basal activation of NLRP3-inflammasome possibly due to the well-known chronic inflammatory state of HIV + patients leading to an "unresponsive" state of monocyte-derived DC \[[@B10]\]. Our findings emphasized once more that this condition is independent of the protocol used for monocyte-DC differentiation.

![**Inflammasome genes expression in IL4-DC and IFN-DC from HIV + subjects pulsed with HIV-1.***mRNA* expression 4 hours after stimulation of IL4-DC and IFN-DC with chemically inactivated HIV-1 was reported for *NLRP1, NLRP3, NLRC4, AIM2, CASP1* and *IL1B* genes **(2A)***.* Fold-change (FC) in mRNA expression of each gene was calculated with respect to the untreated condition as 2^-∆∆Ct^ where ∆∆Ct = ∆Ct HIV- ∆Ct Untreated. Results are expressed as average (AVG) of 2^-∆∆Ct^ ± standard error, n = 20. All the Ct values were normalized against *ACTB* Ct (∆Ct). Stacked lines showed FC threshold (0.5-1.5). 1-way Anova analysis was used to compare genes expression in IFN-DC and IL4-DC. \* = p \< 0.05. **(2B)** Supernatants of IFN-DC and IL4-DC stimulated or not with HIV-1 were analysed for the presence of secreted IL-1β. Results are expressed as the average concentration (pg/ml) ± standard error. 1-way Anova analysis was used to compare IFN-DC and IL4-DC.](1742-6405-10-35-2){#F2}

We are aware that this study is preliminary and that deep investigation about the functionality of IFN-DC is needed, such as ability to activate a lymphocytes specific response, but we would emphasize the importance of DC differentiation protocol in experimental design. Moreover, considering the on-going trials of DC-based immune treatment against HIV-1 \[[@B15]\] it is interesting to remember that the in vitro manipulation of DC could be a limited step in vaccine preparation. Whether it will be fully demonstrated the role of NLRP3-inflammasome in human DC maturation/activation and the impact of inflammasome induction in lymphocyte specific response, our findings suggest that protocols using IL-4 may represent a better choice than IFN ones.
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###### Additional file 1: Figure S1

Characterization of monocyte-derived dendritic cells. Generated immature monocyte-derived dendritic cells obtained through IFN (IFN-DC) (A) or IL-4 (IL4-DC) (B) protocols for common markers expression (CD11c, HLA-DR, CD80, CD86, CD83, CD1a, CCR7). Cells were CD14 negative. Average percentage of positive cells and standard error were reported for healthy individuals (n = 15) stimulated or not with HIV (+HIV and Untreated, respectively).
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